Clik here to view.
How close are we really to “precision medicine” for cancer care?
A newly published paper in the journal JCO Precision Oncology confirms what many of us may have suspected — that the practical application of somatic tissue testing to clinical decision-making was low...
View ArticleMRI data and genomic data are telling us different things about prostate...
A new paper just published on line in the journal PLoS One is entitled, “Association between a 17-gene genomic prostate score and a multi-parametric prostate MRI in men with low and intermediate risk...
View ArticleRisk, genomic risk, and prognosis of risk for prostate cancer metastasis and...
A recently published study in European Urology has again (partially) validated the utility of a specific type of genomic testing as a way to project risk for progressive disease in men initially...
View ArticleBroad Institute launches the Metastatic Prostate Cancer Project
Last May we had told you about an initiative at the Broad Institute in Cambridge, Massachusetts, designed — initially — to generate a comprehensive database of advanced prostate cancer treatment...
View ArticleYour genetics can accurately predict your age-related prostate cancer risk
Data from a new study reported in the British Medical Journal discusses a “polygenic hazard score” that can potentially be used to guide screening for aggressive prostate cancer (but only in men of...
View ArticleCureTalk with Dr. Eli Van Allen on the “Metastatic Prostate Cancer Project”
On Wednesday, February 21, at 5:00 p.m. Eastern time (2:00 p.m. Pacific), we will be collaborating with CureTalks to present the next CureTalk on prostate cancer. It will address the recently launched...
View ArticleThe Metastatic Prostate Cancer Project: listen to the program
Yesterday evening we were pleased to be able to collaborate with CureTalks to host a conversation with Dr. Eli Van Allen — the principal investigator for the Metastatic Prostate Cancer Project — to...
View ArticleNew test now available for identification of AR-V7 mutations in mCRPC
According to a media release issued yesterday, Genomic Health has now made available a commercial test for risk of the AR-V7 mutation in men with metastatic, castration-resistant prostate cancer...
View ArticleGenomic testing and management of low-/intermediate-risk prostate cancer
A new paper has provided us with data on the ability of genomic testing to predict adverse pathology in a man undergoing a multiparametric MRI (mpMRI) and subsequent biopsy for risk of prostate cancer....
View ArticleMedicare to cover genetic/genomic testing in advanced cancers
In an important decision announced late on Friday last week, the Centers for Medicare & Medicaid Services (CMS) announced that it had agreed to cover costs associated with genetic/genomic testing...
View ArticleAre genomic tests for prognostic risk at diagnosis really helpful (yet)?
One of the critical and unanswered questions about the value of genomic/genetic testing in relation to the diagnosis and prognosis of prostate cancer is, “What are the currently available tests...
View ArticleGermline mutations and risk for advanced prostate cancer
Many people are increasingly interested in whether genetic testing can help them to understand their risk for cancer. The basic answer is that “Yes, it can.” However, what is also clear is that it is...
View ArticleGermline genetic testing for men with prostate cancer
In this week’s Journal of Clinical Oncology, there is a full-text article in the “Comments and Controversies” section entitled “Germline testing for men with prostate cancer: navigating an expanding...
View ArticleWhat did we learn at the AUA this year?
The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. Why? Because...
View ArticleGenomic data and prostate cancer risk classification: an update
Three different molecular tests have been validated as providing useful data that can help a man and his doctors to come to decisions about the management and treatment of localized prostate cancer....
View Article